Who We Are

Dr. Nizar Souayah, MD (FAAN, FAANEM, FANA) is the Chairman of the Board of Trustees and CEO of the ALS Institute of New Jersey. He is a triple board-certified neurologist in Neurology, Neuromuscular Medicine, and Electrodiagnostic Medicine, with more than 25 years of clinical and academic leadership in complex neurological and neuromuscular disease.

His training includes Internal Medicine at Hôpital Civil (University of Strasbourg, France), a PGY-1 year at the University of Pennsylvania–Presbyterian Medical Center, Neurology residency at Temple University Hospital (Chief Resident), and a Neuromuscular/EMG fellowship at Massachusetts General Hospital, Harvard Medical School.

Dr. Souayah’s scientific work is deeply aligned with the mission of the ALS Institute of NJ. His major research interests include amyotrophic lateral sclerosis (ALS), neuroinflammation, cell therapy, and outcomes research, with the goal of advancing treatments and improving the quality and cost-effectiveness of ALS care. His peer-reviewed ALS scholarship includes clinical electrodiagnostic research characterizing conduction-slowing patterns in ALS, helping clinicians better interpret complex nerve-testing findings. He also contributes to the broader scientific understanding of ALS disease mechanisms, including work on pathogenic TDP-43 biology.

As a physician-scientist, Dr. Souayah has authored 400+ peer-reviewed publications and has served in editorial roles in neurology journals, reflecting a long-standing commitment to rigorous evidence and transparent scholarship.

In parallel with research, Dr. Souayah is the President and Founding Director of Premier Neuro Health, a secure virtual neurology practice built for complex cases and second opinions—extending access to senior-level expertise for patients and families, including those navigating serious neuromuscular diagnoses.